Safety, Pharmacokinetics and Biodistribution Studies of a β-galactoside Prodrug of Doxorubicin for Improvement of Tumor Selective Chemotherapy

REFERENCES

• Antoniw P., Springer C. J., Bagshawe K. D., Searle F., Melton R. G., Rogers G. T., et al. Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice. Br. J. Cancer 1990; 62: 909–914
   PubMed Web of Science ®Google Scholar
• Bakina E., Wu Z., Rosenblum M., Farquhar D. Intensely cytotoxic anthracycline prodrugs: glucuronides. J. Med. Chem. 1997; 40: 4013–4018
   PubMed Web of Science ®Google Scholar
• Bosslet K., Czech J., Hoffmann D. Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res. 1994; 54: 2151–2159
   PubMed Web of Science ®Google Scholar
• Bosslet K., Czech J., Hoffmann D. A novel one-step tumor-selective prodrug activation system. Tumor Targeting 1995; 1: 45–50
   Google Scholar
• Chabner B. A., Allegra C. J., Curt G. A., Calabresi P. Antineoplastic agents. Goodman and Gilman's the pharmacological basis of therapeutics, J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon, L. S. Gilman, A. Goodman. McGraw-Hill, New York 1996; 1233–1257
   Google Scholar
• Danesi R., Fogli S., Gennari A., Conte P., DelTacca M. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin. Pharmacokinet. 2002; 41: 431–444
   PubMed Web of Science ®Google Scholar
• De Graaf M., Nevalainen T. J., Scheeren H. W., Pinedo H. M., Haisma H. J., Boven E. A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy. Biochem. Pharmacol. 2004; 68: 2273–2281
   PubMed Web of Science ®Google Scholar
• Florent J. C., Dong X., Gaudel G., Mitaku S., Monneret C., Gesson J. P., et al. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. J. Med. Chem. 1998; 41: 3572–3581
   PubMed Web of Science ®Google Scholar
• Gupta M., Mazumder U. K., Rath N., Mukhopadhyay D. K. Antitumor activity of methanolic extract of Cassia fistula L seed against Ehrlich ascites carcinoma. J. Ethanopharmacol. 2000; 72: 151–156
   PubMed Web of Science ®Google Scholar
• Harikrishna D., Raghavendra S. N., Venkateshwarlu Y., Rao A.R., Krishna D.R. β-galactoside prodrugs of doxorubicin for application in antibody directed enzyme prodrug therapy/prodrug monotherapy. Arch. Pharmacal. Res. 2007; 30: 723–732
   PubMed Web of Science ®Google Scholar
• Harikrishna D., Rao A. R., Krishna D. R. Selective activation of anthracycline prodrugs for use in conjunction with ADEPT. Drug News Perspect. 2003; 16: 309–318
   PubMed Web of Science ®Google Scholar
• Hogland H. C. Hematological complications of cancer chemotherapy. Semin. Oncol. 1982; 9: 95–102
   PubMed Web of Science ®Google Scholar
• Houba P. H. J., Boven E., Van Der Meulen-Muileman I. H., Leenders R. G., Scheeren J. W., Pinedo H. M., et al. Distribution and pharmacokinetics of the prodrug daunorubicin-GA3 in nude mice bearing human ovarian cancer xenografts. Biochem. Pharmacol. 1999; 57: 673–680
   PubMed Web of Science ®Google Scholar
• Houba P. H. J., Boven E., Van Der Meulen-Muileman I. H., Leenders R. G. G., Scheeren J. W., Pinedo H. M., et al. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer. Br. J. Cancer 2000; 84: 1–8
   Google Scholar
• Krishna D. R., Sperker B., Fritz P., Klotz U. Does pH 6 beta-galactosidase activity indicate cell senescence?. Mech. Ageing & Dev. 1999; 109: 113–123
   PubMed Web of Science ®Google Scholar
• Leenders R. G. G., Damen E. W., Bijsterveld E. J., Scheeren H. W., Houba P. H., Van Der Meulen-Muileman I. H., et al. Novel anthracycline-spacer-beta-glucuronide,-beta-glucoside, and -beta-galactoside prodrugs for application in selective chemotherapy. Bioorg. Med. Chem. 1999; 7: 1597–1610
   PubMed Web of Science ®Google Scholar
• Maseki M., Nishiagaki I., Hagishara M., Tomada Y., Yagi K. Lipid peroxidation levels and lipid content of serum lipoprotein fractions of pregnant subjects with or without preeclampsia. J. Clin. Chim. Acta 1954; 41: 424–426
   Google Scholar
• Matsuoka H., Sugimachi K., Kuwano H., Yano K. Intratumoural injection of calcium channel blocker enhances cytotoxicity of adriamycin in Ehrlich ascites solid tumour. Eur. J. Surg. Oncol. 1989; 15: 224–231
   PubMedGoogle Scholar
• Mazumder U. K., Gupta M., Maiti S., Mukherjee M. Antitumor activity of hygrophilaspinosa on Ehrlich ascites carcinoma and sarcoma-180 induced mice. Ind. J. Expt. Biol. 1997; 35: 473–477
   PubMedGoogle Scholar
• Michael J. B., Tannock I. F. Lysosomes, lysomal enzymes and cancer. Adv. Cancer Res. 1993; 60: 269–291
   PubMed Web of Science ®Google Scholar
• Price V. E., Greenfield R. E. Anemia in cancer. J. P. Greenstein, H. A. e. JP. Adv. Cancer Res, New York 1958; 199–200
   Google Scholar
• Qureshi S., Al-Harbi M. M., Ahmed M. M., Raza M., Giangreco A. B., Shah A. H. Evaluation of the genotoxic, cytotoxic, and antitumor properties of Commiphora molmol using normal and Ehrlich ascites carcinoma cell-bearing Swiss albino mice. Cancer Chemother. Pharmacol. 1993; 33: 130–138
   PubMed Web of Science ®Google Scholar
• Senter P. D., Springer C. J. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv. Drug Deliv. Rev. 2001; 53: 247–264
   PubMed Web of Science ®Google Scholar
• Springer C. J., Bagshawe K. D., Sharma S. K., Searle F., Boden J. A., Antoniw P., et al. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur. J. Cancer 1991; 27: 1361–1366
   PubMed Web of Science ®Google Scholar
• Wallace P. M., Macmaster J. F., Smith V. F., Kerr D. E., Senter P. D., Cosand W. L. Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res. 1994; 54: 2719–2723
   PubMed Web of Science ®Google Scholar